In a double-blind, multicenter trial, 541 febrile granulocytopenic patients were randomized to receive either intravenous (iv) clinafloxacin (200 mg every 12 h) or iv imipenem (500 mg every 6 h) as empirical monotherapy. 
frequently. Recently, several studies have shown that monotherapy with ceftazidime, imipenem, cefepime, or meropenem can be as effective as combination therapy [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Because of the increasing incidence of grampositive infections in febrile granulocytopenic patients, a third option is to use vancomycin in combination with ceftazidime [1, 13, 14] .
Although each of these regimens is effective in the majority of patients, all have certain limitations. Many granulocytopenic patients receive other nephrotoxic drugs (amphotericin B, cyclosporine, and certain chemotherapeutic agents), which makes concomitant use of the aminoglycosides potentially hazardous. Ceftazidime lacks significant activity for coagulase-negative staphylococci, Staphylococcus aureus, and other gram-positive organisms that now commonly cause infection in granulocytopenic patients [8, 12, 15] . Monotherapy with ceftazidime can also be associated with the emergence of b-lactam-resistant gram-negative bacillary organisms [16] . Gastrointestinal toxicity, seizures, and superinfections with Stenotrophomonas maltophilia may complicate imipenem therapy [5] [6] [7] [8] 17] . The use of cefepime, with its better coverage of gram-positive organisms, or meropenem, with its excellent safety profile, may overcome some of the shortcomings of treatment with ceftazidime or imipenem. However, these newer agents are costly and have not been shown in controlled clinical trials to have any significant advantages over other b-lactam drugs [9] [10] [11] [12] 18] . Because of cross-allergies, neither the cephalosporins nor the carbapenems can be used comfortably in patients with histories of severe hypersensitivity reactions to b-lactam drugs [19] . Finally, the association of vancomycin-resistant enterococcal infections with the excessive use of vancomycin has made the inclusion of vancomycin as part of any empirical antimicrobial regimen less desirable [20] .
Clinafloxacin is a new broad-spectrum fluoroquinolone with enhanced activity for a wide range of gram-positive, gramnegative, and anaerobic organisms [21] . Clinafloxacin retains the activity of the older fluoroquinolones against Pseudomonas aeruginosa and other gram-negative bacilli but is much more active against gram-positive bacteria and anaerobic organisms [22, 23] . In vitro, clinafloxacin is especially active against the Enterobacteriaceae, P. aeruginosa, staphylococci, and streptococci, as well as many organisms resistant to ciprofloxacin and the b-lactam drugs.
The role of the fluoroquinolones in the empirical treatment of febrile granulocytopenic patients has not been firmly established. Monotherapy with ciprofloxacin or ofloxacin has produced both favorable and unfavorable results and is generally not recommended [1, 24, 25] . Similarly, studies of quinolone drugs as part of combination therapy have mostly involved small numbers of patients and provided inconclusive results [1, 24, 26] . For these reasons, we performed a randomized, double-blind multicenter study to compare the efficacy and safety of clinafloxacin with imipenem as monotherapy for febrile granulocytopenic patients. Imipenem was chosen as the comparative agent because some previous trials [6, 27] had found imipenem alone to be more effective than ceftazidime alone in febrile granulocytopenic patients and many of the study sites participating in this trial had concerns about the presence of b-lactamase-producing gram-negative bacillary organisms resistant to ceftazidime [16] .
PATIENTS AND METHODS

Patients.
Hospitalized patients were eligible for enrollment in the study if they satisfied the following criteria: у18 years old; hematologic malignancy or solid tumor; granulocyte count р500/mm 3 or р1000/mm 3 and expected to fall below 500/ mm 3 within 48 h of starting treatment with study drug; 2 measurements of elevated temperature 138ЊC or 1 temperature measurement of 138.3ЊC unrelated to the administration of blood products or drugs; no allergy to b-lactam drugs or quinolones; and no history of seizures. Patients were excluded from the study if any of the following criteria applied: severe hepatic disease (defined as an increase in the level of total serum bilirubin 13 times normal or in the level of serum aspartate aminotransferase or serum alanine aminotransferase 15 times normal); requirement for dialysis; infection with HIV; treatment with a quinolone within 7 days of randomization; or previous enrollment in the study. Women were required to have a negative test for pregnancy.
Antibiotic regimens. Eligible patients at each study site were randomly assigned in a double-blind fashion to receive either clinafloxacin or imipenem. Randomization was done in a 1:1 ratio and stratified by type of underlying malignancy (hematologic or solid tumor) and by whether the patient had received a bone marrow or stem cell transplant. Clinafloxacin (Parke-Davis) was given iv at a dosage of 200 mg every 12 h. The imipenem (Primaxin; Merck) dosage was 500 mg iv every 6 h. Patients assigned to receive clinafloxacin every 12 h also received an iv placebo (100 mL of 5% dextrose in water) every 12 h so that an iv infusion was given every 6 h. Each dose of study medication was infused over an interval of 60 min. The doses of clinafloxacin and imipenem were adjusted for patients with impaired renal function by a pharmacist not blinded to the patient's study drug. The dosage of clinafloxacin was decreased to 100 mg iv every 12 h for patients with creatinine clearance of 10-50 mL/min and to 100 mg iv every 24 h for patients with creatinine clearance of !10 mL/min. The dosage of imipenem was decreased to 500 mg iv every 12 h for patients with creatinine clearance of !40 mL/min. Laboratory studies. Before the start of therapy, specimens of blood and from other suspected sites of infection were obtained for culture. Patients with bacteremia or a documented site of infection associated with a positive result of culture had additional cultures performed during and after therapy, unless the site of infection was not accessible for repeated sampling. All organisms isolated from clinical specimens were identified by standard criteria in the clinical microbiology laboratory at each study site and confirmed by a reference laboratory (SciCor) [28] . Similarly, the antimicrobial susceptibility of bacterial isolates to clinafloxacin, imipenem, and other antimicrobial agents was tested by the disk diffusion and broth microdilution methods at both the study site and the reference laboratory [29] . Susceptibility break points were as follows: clinafloxacin, MIC р1 mg/mL or a zone of inhibition у21 mm (5 mg disk); imipenem, MIC р4 mg/mL or zone у16 mm (10 mg disk).
Complete blood cell counts, prothrombin and partial thromboplastin times, determinations of serum electrolyte, creatinine, and blood urea nitrogen levels, urinalyses, and liver function tests (total bilirubin, aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase levels) were performed before, during, and after therapy to assess possible treatmentrelated side effects. Patients were also examined during and after therapy for clinical symptoms and signs of side effects related to the study antibiotics. All side effects, adverse events, or abnormal laboratory values that occurred during the study were recorded and classified blindly by investigators as unrelated, possibly related, or definitely related to the study drug.
Evaluation of response. Initial febrile episodes were classified as caused by one of the following: microbiologically documented infection (both site of infection and organism identified), clinically documented infection (site of infection identified but no organism isolated), or possible infection (infection suspected but no site or organism identified). The response to therapy was classified as improvement (disappearance of fever, overall clinical improvement, and eradication of any infecting organism without modification of antibiotic therapy) or failure (persistence of fever or of the infecting organism requiring modification of antibiotic therapy or any death during treatment with the study drug). Criteria for modifying initial treatment with the study drug included persistence or worsening of clinical symptoms and signs of infection, resistance of the baseline bacterial pathogen to the study drug, persistence of the initial pathogen despite therapy, or emergence of a new pathogen or focus of infection. Superinfection was defined as a new microbiologically documented infection that occurred either during therapy or within 7 days of the discontinuation of antibiotic therapy. All classifications of infection and responses to therapy were done by investigators blinded to the patient's study therapy.
Statistical analysis. Data summaries and analyses were performed by use of SAS version 6.09 [30] . All statistical tests were done as 2-tailed tests. The Cochran-Mantel-Haenszel test was used to compare differences in proportions. Times to specific events were compared by using Kaplan-Meier analysis and the log rank test [31] . Treatment interactions by center and type of malignancy were determined by using the Breslow-Day test [32] . All patients were included in both the efficacy and safety analyses (intent-to-treat analysis).
RESULTS
Patient characteristics.
A total of 541 patients from 15 medical centers in the United States and Canada were entered into the trial from November 1994 through August 1996. There were 272 patients in the clinafloxacin group and 269 patients in the imipenem group. Patients in the 2 treatment groups were of similar age, sex, underlying disease, degree and duration of granulocytopenia, and use of hematopoietic growth factors (table 1). A total of 149 (55%) of 272 patients in the clinafloxacin group and 153 (57%) of 269 patients in the imipenem group had received a bone marrow or stem cell transplant. Most patients in both groups had initial granulocyte counts of !100 cells/mm 3 . Persistent granulocytopenia (!500 granulocytes/ mm 3 throughout the course of therapy with study drug) was associated with ∼25% of the treatment courses. About 40% of the febrile episodes in each treatment group were caused by either a microbiologically documented infection (bacteremia or localized bacterial infection) or a clinically documented infection. The median duration of therapy with study drug was 10 days in each treatment group.
Susceptibility of pretherapy isolates to antibiotics. Baseline organisms from both treatment groups were tested for susceptibility to both clinafloxacin and imipenem. Among pretherapy gram-negative organisms available for susceptibility testing, 146 (100%) of 146 were susceptible to clinafloxacin and 145 (98%) of 148 were susceptible to imipenem. Among pretherapy gram-positive organisms available for susceptibility testing, 113 (97%) of 116 were susceptible to clinafloxacin and 108 (92%) of 117 were susceptible to imipenem. Thus, 259 (99%) of 262 baseline organisms tested for susceptibility were susceptible to clinafloxacin, whereas 253 (95%) of 265 baseline organisms were susceptible to imipenem ( ). The 3 base-P p .03 line organisms not susceptible to clinafloxacin were 2 isolates of coagulase-negative staphylococci and 1 isolate of Enterococcus faecalis. The 12 baseline organisms not susceptible to imipenem were 8 isolates of coagulase-negative staphylococci, 1 isolate of Corynebacterium species, and 3 isolates of S. maltophilia.
Clinical response to therapy. ). The response P p .24 rates for localized bacterial infections, clinically documented infections, and possible infections were similar for each treatment group. The median time to defervescence was 4 days for both treatment groups.
The most common reason for failure of initial monotherapy with clinafloxacin or imipenem was the addition of other antimicrobial agents ( Only 13 treatment failures (5%) in the clinafloxacin group and 18 (7%) in the imipenem group were caused by death of the patient during the study. Only 1 clinafloxacin recipient and 1 imipenem recipient died from a baseline infection. The clinafloxacin recipient was treated with study drug for fever related to possible but undocumented infection and died of multiorgan failure and a clinical syndrome consistent with sepsis. The imipenem recipient died of septic shock related to baseline bacteremia caused by Klebsiella pneumoniae, viridans group streptococci, and coagulase-negative staphylococci. Other causes of death in the clinafloxacin group were clinical sepsis with negative cultures (1 patient), fungal superinfection (4 patients), toxicity from chemotherapy (4), underlying malignancy (2), and hemorrhage (1) . Other causes of death in the imipenem group were fungal superinfection (4), toxicity from chemotherapy (4), underlying malignancy (6), hemorrhage (2), and graft-versus-host disease (1) .
Response by bacterial pathogen. Table 3 compares the response to therapy according to bacterial pathogen. Among 286 baseline pathogens, 159 (56%) were gram-negative organisms and 127 (44%) were gram-positive bacteria. Escherichia coli and Klebsiella species were the most common gram-negative baseline pathogens, whereas coagulase-negative staphylococci and viridans group streptococci were the most common gram-positive baseline pathogens.
Eighteen (23%) of 79 gram-negative infections in the clinafloxacin group and 20 (25%) of 80 gram-negative infections in the imipenem group improved during treatment with study drug alone. Most other gram-negative infections in each treatment group improved after modification with additional antimicrobial agents. However, more gram-negative infections in the imipenem group (15%) were associated with death during the study than were gram-negative infections in the clinafloxacin group (5%;
; table 3). Similarly, although most P p .06 gram-positive infections in each treatment group responded to either the study drug alone (20% for clinafloxacin vs. 33% for imipenem) or subsequent modified therapy with other agents (80% for clinafloxacin vs. 54% for imipenem), more grampositive infections were associated with death in the imipenem group (13%) than in the clinafloxacin group (none) during the study (  ; table 3 ). Overall, 20 documented bacterial P p .003 infections in the imipenem group compared with only 4 in the clinafloxacin group were associated with death during the study (  ; table 3 ). Nevertheless, except for 1 case of bacteremia P p .001 in an imipenem recipient caused by K. pneumoniae, viridans group streptococci, and coagulase-negative staphylococci, none of these gram-negative or gram-positive infections were considered by investigators (blinded to the study drug) to be the primary cause of death. No baseline organism susceptible to clinafloxacin or imipenem before treatment developed resistance to that study drug during therapy.
Response related to duration of granulocytopenia. The response of patients was also evaluated in relation to the duration of granulocytopenia (granulocyte count р500 cells/ mm 3 ) during the study. Among patients with granulocytopenia р7 days' duration after starting the study drug, the response rates were 53 (34%) of 157 patients in the clinafloxacin group and 57 (33%) of 172 patients in the imipenem group. Similarly, among patients with granulocytopenia 17 days' duration after starting the study drug, the response rates were 35 (30%) of 115 patients in the clinafloxacin group and 32 (33%) of 97 patients in the imipenem group. None of these differences was significant.
Superinfections. ), the types of bacterial P p .14 and fungal organisms causing superinfections were similar for each study drug. Candida and Aspergillus species were the most common fungal organisms causing superinfection. Three (19%) of 16 bacterial organisms causing superinfection in the clinafloxacin group and 7 (47%) of 15 bacterial organisms causing superinfection in the imipenem group were resistant to clinafloxacin and imipenem, respectively ( ). P p .13 Antibiotic-related adverse events. A total of 85 (32%) of 270 patients in the clinafloxacin group and 69 (26%) of 265 in the imipenem group experienced adverse events possibly or definitely related to the study drug ( ). The most com-P p .18 mon and significant adverse events associated with each study drug are shown in table 5. Skin rashes were more common in patients treated with clinafloxacin. On the other hand, nausea and diarrhea associated with Clostridium difficile occurred more often in patients receiving imipenem. Seizures related to study drug occurred only in patients treated with imipenem. Drugrelated nephrotoxicity or liver dysfunction was very uncommon with either study drug. One patient treated with clinafloxacin experienced a moderate photosensitivity reaction involving the face on day 3 of therapy, which resolved after the clinafloxacin was discontinued. Drug-related hypoglycemia (serum glucose level, 44-67 mg/dL) occurred in only 4 clinafloxacin recipients and was symptomatic (diaphoresis and shakiness) in 2. Drugrelated adverse events caused discontinuation of study drug in 13 clinafloxacin recipients (5%) and in 21 imipenem recipients (8%). Skin rash (7 patients), pruritus (1), nausea (1), vomiting (1), altered mental status (1), hypotension (1), and a photosensitivity reaction (1) were the drug-related adverse events leading to discontinuation of clinafloxacin. Skin rash (11 patients), nausea (4), diarrhea (1), seizures (3), fever (1), and altered mental status (1) were the drug-related adverse events leading to discontinuation of imipenem.
DISCUSSION
Recently, several randomized, controlled trials have demonstrated that monotherapy with newer, extended-spectrum bactericidal cephalosporins (ceftazidime, cefepime) or carbapenems (imipenem, meropenem) is an effective alternative to traditional combination therapy in febrile granulocytopenic patients [2-6, 10, 12] . Potential advantages of monotherapy are less toxicity, decreased costs, and simplicity of administration. Consequently, at many oncology centers, single-agent therapy with ceftazidime or imipenem is now standard for suspected bacterial infection in the granulocytopenic patient.
Use of the fluoroquinolones as monotherapy for the febrile granulocytopenic patient has been controversial. Initial trials in small numbers of febrile granulocytopenic patients with bac- teremias, pneumonias, and soft-tissue infections suggested that single-agent therapy with iv ciprofloxacin is effective [24, 33, 34] . However, a subsequent prospective, randomized comparison of iv ciprofloxacin monotherapy with a combination regimen of piperacillin plus amikacin done by the European Organization for Research and Treatment of Cancer (EORTC) found that ciprofloxacin was less effective as empirical therapy for febrile granulocytopenic patients [35] . This study was discontinued prematurely because patients treated with ciprofloxacin alone had a significantly lower response rate (31 [65%] of 48 patients) than did patients treated with piperacillin plus amikacin (48 [91%] of 53 patients;
). Patients with P p .002 gram-positive bacteremia had a particularly poor outcome. Similar trials evaluating oral ofloxacin alone versus combinations of parenteral antibiotics in febrile granulocytopenic patients also provided inconclusive results [36, 37] . Consequently, current guidelines established by the Infectious Diseases Society of America and other experts for use of antimicrobial agents in granulocytopenic patients have not recommended quinolone monotherapy [1, 25] .
Clinafloxacin is much more active relative to ciprofloxacin, other older fluoroquinolones, and b-lactam drugs against grampositive bacteria, while maintaining excellent activity for P. aeruginosa and other gram-negative bacillary pathogens [21] [22] [23] . Clinafloxacin alone was found to be as effective as imipenem alone for empirical therapy, in this present doubleblind trial, which is the largest trial of quinolone monotherapy in febrile granulocytopenic patients ever reported. A total of 99% of all gram-positive and gram-negative baseline pathogens were susceptible to clinafloxacin, and there were no substantial differences in the overall clinical responses to treatment with clinafloxacin (32%) or imipenem (33%). As in other multicenter trials of empirical antibiotic therapy among febrile granulocytopenic patients [12, 18, 26] , most patients in this trial had modification of their monotherapy to achieve a successful outcome. Nonetheless, only 1 patient of each treatment group NOTE. Data in parentheses indicate isolates resistant to study drug (clinafloxacin, MIC 12 mg/mL; imipenem, MIC 18 mg/mL). a vs. clinafloxacin. P p .14 died from their baseline infection, and overall mortality during the study was low in both groups (13 [5%] of 272 with clinafloxacin, 18 [7%] of 269 with imipenem).
The initial response rates observed for both groups in this study (88 [32%] of 272 with clinafloxacin, 89 [33%] of 269 with imipenem) were relatively low. However, in accordance with recent guidelines from the US Food and Drug Administration and previously proposed by the Immunocompromised Host Society and the Infectious Diseases Society of America, any modification of the study antibiotic regimen was considered a treatment failure [38] [39] [40] . In many cases, additional antibiotics were given despite negative results of follow-up cultures and the absence of any clinical deterioration. Using similar criteria for failure, other recent trials evaluating ceftazidime, imipenem, meropenem, or ciprofloxacin either as monotherapy or as part of a combination regimen have also observed rates of response as low as 21%-54% among patients whose therapy was not modified [7, 11, 12, 18, 26] . Furthermore, cefepime recently became the first antibiotic approved by the US Food and Drug Administration for monotherapy for febrile granulocytopenic patients on the basis of pooled response rates without modification of therapy of 34% and pooled response rates with modification of therapy of 93% [41] . These response rates with cefepime are similar to the response rates seen with clinafloxacin and imipenem in this study. Finally, in contrast to most other studies, our study was double-blinded, which prevented primary physicians from knowing which study drug was being given to a patient. This blinding could have contributed to more frequent modifications of therapy by physicians who were uncomfortable about the antibiotic that was being used to treat seriously ill patients who did not show immediate improvement.
Expanded use of the fluoroquinolones worldwide has been associated with a gradual emergence of resistance among P. aeruginosa, E. coli, and other organisms in certain countries [42] . Such resistance needs to be considered when evaluating the appropriateness of empirical monotherapy with clinafloxacin or other newer quinolones at a particular institution. There is also concern that single-agent therapy with a fluoroquinolone for febrile granulocytopenic patients could foster the development and spread of resistant organisms. Indeed, when fluoroquinolones have been used for prophylaxis of infection in granulocytopenic patients, there has been a reduction in gram-negative bacillary infections at the expense of an increased risk for gram-positive bacterial infections caused by quinoloneresistant organisms, especially viridans group streptococci [24, 43] . Occasional emergence of quinolone-resistant gram-negative bacilli has also been observed in patients given quinolone prophylaxis [44] . In this study, in which clinafloxacin was used for empirical therapy rather than prophylaxis of infection, 99% of all baseline pathogens were sensitive to clinafloxacin and none developed resistance to clinafloxacin during treatment. Furthermore, only 3 (1.1%) of 272 patients had superinfections caused by bacterial organisms resistant to clinafloxacin. Thus, reserving use of a broad-spectrum fluoroquinolone such as clinafloxacin for treatment rather than prevention of infection may be associated with less emergence of quinolone-resistant organisms. Of note, excluding patients from this study who previously took a quinolone for prophylaxis may have also contributed to the low incidence of quinolone resistance and a greater number of baseline gram-negative infections relative to gram-positive infections (table 3) .
Both clinafloxacin and imipenem were generally well tolerated in this trial. Recently, reports of severe liver injury with trovafloxacin and of cardiac arrhythmias with grepafloxacin have raised concerns about the safety of newer fluoroquinolones [45, 46] . A third fluoroquinolone, temafloxacin, was re- moved from the market in the early 1990s because of the unusual occurrence of an immune hemolytic anemia syndrome [47] . We were unable to note any hepatic, cardiac, or hematologic toxicity related to clinafloxacin in this study. A thorough review of liver-related adverse events, cardiac arrhythmias, and hematologic abnormalities in all investigational clinical trials involving clinafloxacin also found a similar occurrence of these adverse events among patients treated with clinafloxacin and those receiving comparative drugs [48] . The higher incidence of gastrointestinal adverse events (nausea, C. difficile-associated diarrhea) and seizures among patients receiving imipenem in this study has also been reported in other trials that evaluated imipenem in febrile granulocytopenic patients [5] [6] [7] [8] 17] . Hypoglycemic reactions and photosensitivity, which occurred in 4 and 1 clinafloxacin recipients, respectively, in this study (table 5) , appear to happen more frequently among patients treated with clinafloxacin than among patients treated with other classes of antimicrobial agents. Clinafloxacin and other quinolones can stimulate insulin release and thereby induce hypoglycemia [49] . Quinolones also absorb light in the UV spectrum, which can cause degradation of the drug and the release of toxic free radicals and oxygen products [50] . The overall incidences of drug-related hypoglycemia and phototoxicity in 11500 patients treated with clinafloxacin during investigational clinical trials were 2.5% and 2.1%, respectively [48] . Phototoxicity has been noted more often in patients treated with oral clinafloxacin (16% incidence) than in patients receiving iv clinafloxacin (1% incidence). The very low incidence of phototoxicity observed with iv clinafloxacin in this study was likely related to its exclusive use in seriously ill hospitalized patients with limited sunlight exposure.
The overall mortality rate during this study was similar for the clinafloxacin and imipenem groups. However, more microbiologically documented baseline infections in the imipenem group (20 patients) than in the clinafloxacin group (4 patients) were associated with death during the study (table 3) . Only 1 of these baseline infections (a case of polymicrobial bacteremia in the imipenem group) was considered by investigators blinded to the study drug to be the primary cause of death. Thus, although the lower mortality rate among patients with microbiologically documented baseline infections treated with clinafloxacin is noteworthy, other noninfectious factors may have been responsible for the different mortality rates of the 2 treatment groups.
Another potential use for quinolone monotherapy is the outpatient treatment of low-risk patients with fever and granulocytopenia. Low-risk patients with fever and granulocytopenia have been characterized as granulocytopenic patients with stable cancer who develop fever as outpatients, have no serious concurrent underlying condition, and are expected to have a duration of granulocytopenia р7 days [51] . In this situation, oral therapy with a combination of ciprofloxacin plus amoxicillin-clavulanate or ofloxacin alone has been reported to be as effective as iv therapy [36, 37, 52, 53] . Most patients in our study, which included many patients who had undergone transplantation or who had advanced malignancy, were high-risk patients. The broader antibacterial spectrum of clinafloxacin relative to ciprofloxacin and other quinolones, however, could facilitate the outpatient management of low-risk febrile granulocytopenic patients. Levofloxacin, an approved quinolone with an antibacterial spectrum similar to clinafloxacin, is currently being evaluated in randomized controlled trials as monotherapy for both inpatients and low-risk outpatients with fever and granulocytopenia [54] .
In summary, the results of this large, randomized, doubleblind trial suggest that monotherapy with clinafloxacin is a suitable option for empirical treatment of febrile granulocytopenic patients. Patients who are intolerant of b-lactam drugs because of hypersensitivity or bacterial resistance or of the aminoglycosides due to toxicity may especially benefit from clinafloxacin monotherapy. 
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